Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Outcomes of Eltrombopag in Bone Marrow Aplasia
NCT06493981Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Assiut University. Primary endpoints: Hematological response at 6 months and Overall Survival at 5 years. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06493981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493981.